Latest Governance News

The Takeovers Panel has declined to find unacceptable circumstances in Diamond Infraco’s bid for Atlas Arteria, accepting ASIC relief and an undertaking that address concerns over the conditional price increase mechanism.

Nex Metals Explorations and the Wangkatja Tjungula Aboriginal Corporation have formalised a joint venture to combine WTAC’s capital and cultural knowledge with Nex Metals’ technical expertise to pursue gold projects in Western Australia.

Island Pharmaceuticals has appointed Raymond Taylor, a former BioCryst executive with deep Galidesivir expertise and US government funding experience, to accelerate development and procurement efforts for its broad-spectrum antiviral amid rising viral threats.

Comet Ridge has revised its acquisition deal for Santos’ stake in the Mahalo Gas Project, cutting upfront cash and extending deadlines to navigate new government gas reservation policy uncertainty.

Eden Innovations appoints former European Parliament member Antanas Guoga to lead EdenShield’s push into European defence and critical infrastructure markets amid surging regional security spending.

Lion Rock Minerals has brought in a seasoned leadership team from Sierra Rutile to spearhead development at its Minta Rutile and Monazite Project in Cameroon, supported by a $2 million capital raise.

IperionX has commissioned a cutting-edge six-axis SACMI powder metallurgy press in Virginia, tripling its titanium manufacturing capacity and enabling production of complex components for defense and aerospace markets.

Arafura Rare Earths has committed to constructing the Nolans Rare Earths Project, Australia's first fully integrated ore-to-oxide operation, backed by binding offtake deals and sovereign financing. Construction is slated to start in September 2026, positioning Nolans as a strategic node in global rare earth supply chains.

Ventia Services Group reported a strong FY25 with revenue of $6.1 billion and 13% NPATA growth, while CEO Dean Banks announced his planned departure later this year. The company reaffirmed its FY26 guidance and highlighted growth opportunities in Defence, Digital Infrastructure, Energy, and Water.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

TruScreen Group Limited has kicked off a NZ$2.9 million capital raising combining a NZ$1 million placement and a NZ$1.94 million rights issue to fund its global expansion and regulatory compliance efforts. The company reported a 42% jump in product sales for FY2026 and is targeting major public health programs across 14 countries.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.